Dexfenfluramine

Jump to: navigation, search
Dexfenfluramine
Dexfenfluramine.png
Clinical data
ATC code
Legal status
Legal status
  • Schedule IV (US DEA)
Pharmacokinetic data
Protein binding36%
Elimination half-life17-20 hours
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC12H16F3N
Molar mass231.257 g/mol

WikiDoc Resources for Dexfenfluramine

Articles

Most recent articles on Dexfenfluramine

Most cited articles on Dexfenfluramine

Review articles on Dexfenfluramine

Articles on Dexfenfluramine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Dexfenfluramine

Images of Dexfenfluramine

Photos of Dexfenfluramine

Podcasts & MP3s on Dexfenfluramine

Videos on Dexfenfluramine

Evidence Based Medicine

Cochrane Collaboration on Dexfenfluramine

Bandolier on Dexfenfluramine

TRIP on Dexfenfluramine

Clinical Trials

Ongoing Trials on Dexfenfluramine at Clinical Trials.gov

Trial results on Dexfenfluramine

Clinical Trials on Dexfenfluramine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Dexfenfluramine

NICE Guidance on Dexfenfluramine

NHS PRODIGY Guidance

FDA on Dexfenfluramine

CDC on Dexfenfluramine

Books

Books on Dexfenfluramine

News

Dexfenfluramine in the news

Be alerted to news on Dexfenfluramine

News trends on Dexfenfluramine

Commentary

Blogs on Dexfenfluramine

Definitions

Definitions of Dexfenfluramine

Patient Resources / Community

Patient resources on Dexfenfluramine

Discussion groups on Dexfenfluramine

Patient Handouts on Dexfenfluramine

Directions to Hospitals Treating Dexfenfluramine

Risk calculators and risk factors for Dexfenfluramine

Healthcare Provider Resources

Symptoms of Dexfenfluramine

Causes & Risk Factors for Dexfenfluramine

Diagnostic studies for Dexfenfluramine

Treatment of Dexfenfluramine

Continuing Medical Education (CME)

CME Programs on Dexfenfluramine

International

Dexfenfluramine en Espanol

Dexfenfluramine en Francais

Business

Dexfenfluramine in the Marketplace

Patents on Dexfenfluramine

Experimental / Informatics

List of terms related to Dexfenfluramine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. After it was removed in the US, dexfenfluramine was also pulled out in other global markets. It was later superseded by sibutramine, which is a safer alternative to both dexfenfluramine and fenfluramine.

The drug was manufactured by Interneuron Pharmaceuticals and marketed by Wyeth-Ayerst Laboratories. It is the enantiomer of levofenfluramine.

See also

References


Linked-in.jpg